Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information from Marketing Authorisation Holders of products containing Infliximab (Remicade, Flixabi, Inflectra, and Remsima): Use of live vaccines in infants exposed in utero or during breastfeeding
Important Safety Information – Infliximab (Remicade, Flixabi, Inflectra, and Remsima)